We observed that the CLEC11A expression was significantly elevated in breast invasive carcinoma, cholangiocarcinoma, colon adenocarcinoma, head and neck squamous cell carcinoma, LUAD, prostate adenocarcinoma, and STAD. Here, CLEC11A is linked to prostate adenocarcinoma.